National approaches to managing cancer care: responses of countries in the MENA region to the COVID-19 pandemic.
COVID-19
MENA region
cancer care
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
11
2020
entrez:
23
4
2021
pubmed:
24
4
2021
medline:
24
4
2021
Statut:
epublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic presents serious challenges to cancer care because of the associated risks from the infection itself and the disruption of care delivery. Therefore, many professional societies have published recommendations to help manage patients with cancer during the current pandemic. The objective of our study is to assess the national responses of Middle East North Africa (MENA) countries in terms of publishing relevant guidelines and analyse various components of these guidelines. A survey based on the preliminary review of the literature regarding cancer care adaptations has been developed and then completed by a group of oncologists from the following Arab countries affected by the pandemic: Algeria, Egypt, Iraq, Jordan, Kuwait, Lebanon, Morocco, Oman, Saudi Arabia, Syria, Tunisia, United Arab Emirates and Yemen. The survey inquired about COVID-19 cases, national recommendations regarding general measures of COVID-19 prevention and patient care in oncology as well as their implementation about cancer care adaptations during the pandemic. Analysis of the COVID-19 pandemic-related guidelines revealed at least 30 specific recommendations that we categorised into seven essential components. All included countries had national guidelines except one country. Estimated full compliances with all specific category recommendations ranged from 30% to 69% and partial compliance ranged from 23% to 61%. There is a very good response and preparedness in the Arab Middle East and North Africa region surveyed. However, there are inconsistencies in the various components of the guidelines across the region, which reflects the evolving status of the pandemic in each country as well as the lack of clear evidence-based guidelines for many of the issues in question. There is a need for a clear framework on essential components that should be included in these guidelines to assure providing the best guidance to the oncology community.
Sections du résumé
BACKGROUND
BACKGROUND
The coronavirus disease 2019 (COVID-19) pandemic presents serious challenges to cancer care because of the associated risks from the infection itself and the disruption of care delivery. Therefore, many professional societies have published recommendations to help manage patients with cancer during the current pandemic. The objective of our study is to assess the national responses of Middle East North Africa (MENA) countries in terms of publishing relevant guidelines and analyse various components of these guidelines.
METHODS
METHODS
A survey based on the preliminary review of the literature regarding cancer care adaptations has been developed and then completed by a group of oncologists from the following Arab countries affected by the pandemic: Algeria, Egypt, Iraq, Jordan, Kuwait, Lebanon, Morocco, Oman, Saudi Arabia, Syria, Tunisia, United Arab Emirates and Yemen. The survey inquired about COVID-19 cases, national recommendations regarding general measures of COVID-19 prevention and patient care in oncology as well as their implementation about cancer care adaptations during the pandemic.
RESULTS
RESULTS
Analysis of the COVID-19 pandemic-related guidelines revealed at least 30 specific recommendations that we categorised into seven essential components. All included countries had national guidelines except one country. Estimated full compliances with all specific category recommendations ranged from 30% to 69% and partial compliance ranged from 23% to 61%.
CONCLUSION
CONCLUSIONS
There is a very good response and preparedness in the Arab Middle East and North Africa region surveyed. However, there are inconsistencies in the various components of the guidelines across the region, which reflects the evolving status of the pandemic in each country as well as the lack of clear evidence-based guidelines for many of the issues in question. There is a need for a clear framework on essential components that should be included in these guidelines to assure providing the best guidance to the oncology community.
Identifiants
pubmed: 33889198
doi: 10.3332/ecancer.2021.1189
pii: can-15-1189
pmc: PMC8043675
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1189Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
Zineb Benbrahim received educational grants from Novartis, MSD, AstraZeneca. Humaid O Al Shamsi received research support from ROCHE. AR Jazieh received research funds from MSD.
Références
Lancet Oncol. 2020 May;21(5):619-621
pubmed: 32220659
Future Oncol. 2020 Nov;16(31):2551-2567
pubmed: 32715776
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
J Med Microbiol. 2003 Aug;52(Pt 8):715-720
pubmed: 12867568
Crit Care. 2019 Mar 27;23(1):99
pubmed: 30917856
JCO Glob Oncol. 2020 Mar;6:518-524
pubmed: 32216653
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
Oncologist. 2020 Jun;25(6):e936-e945
pubmed: 32243668
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Ecancermedicalscience. 2020 Jun 17;14:1060
pubmed: 32582375
Nat Rev Clin Oncol. 2020 May;17(5):268-270
pubmed: 32242095
Future Oncol. 2020 Apr;16(11):615-617
pubmed: 32266838
Cancer. 2020 Sep 15;126(18):4235-4245
pubmed: 32648950
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977